New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy

Mostrar otras versiones (1)

Rectal cancer ranks as the second leading cause of cancer-related deaths. Neoadjuvant therapy for rectal cancer patients often results in individuals that respond well to therapy and those that respond poorly, requiring life-altering excision surgery. It is inadequately understood what dictates this...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerber, Scott, Uccello, Taylor, Lesch, Maggie, Kintzel, Sarah, Gradzewicz, Lauren, Lamrous, Lillia, Murphy, Shawn, Fleming, Fergal, Mills, Bradley, Murphy, Joseph, Hughson, Angela, Garrett-Larsen, Jesse, Qiu, Haoming, Drage, Michael, Ye, Jian, Gavras, Nicholas, Keeley, David, Love, Tanzy, Repasky, Elizabeth, Lord, Edith, Linehan, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120761/
https://www.ncbi.nlm.nih.gov/pubmed/37090639
http://dx.doi.org/10.21203/rs.3.rs-2767780/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120761/
https://www.ncbi.nlm.nih.gov/pubmed/37090639
http://dx.doi.org/10.21203/rs.3.rs-2767780/v1

Ejemplares similares